Design, synthesis and biological evaluation of novel peptides as potential agents with anti-tumor and multidrug resistance-reversing activities

Amino Acids. 2017 Aug;49(8):1355-1364. doi: 10.1007/s00726-017-2434-1. Epub 2017 May 4.

Abstract

Tumor chemotherapy is an important mean in the clinical treatment of metastatic cancer,but low selectivity and drug resistance restrict its clinical application. BP100 is a multifunctional membrane-active peptide with high antimicrobial activity. We selected BP100 as a lead peptide, designed and synthesized a series of BP100 analogs through solid-phase synthesis. Amongst them, peptides with the Tyr10 residue substituted by leucine and histidine showed the highest anti-cancer activity. Further experiments revealed that BP100 and its analogs could disrupt the cell membrane and trigger the cytochrome C release into cytoplasm, which ultimately resulted in apoptosis. Meanwhile, BP100 and its analogs also exhibited effective anti-tumor activity against multidrug-resistant cells, showing multidrug resistance-reversing effects. In conclusion, these peptides might be promising candidates for cancer therapy.

Keywords: Anti-cancer; Antimicrobial peptides; Membrane-disruption; Multidrug resistance-reversing effects.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemical synthesis*
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Cell Membrane / drug effects
  • Cell Membrane / metabolism
  • Cell Proliferation / drug effects
  • Drug Design*
  • Drug Resistance, Multiple / drug effects*
  • Humans
  • Mitochondria / drug effects
  • Neoplasms / drug therapy
  • Neoplasms / pathology*
  • Oligopeptides / chemical synthesis
  • Oligopeptides / pharmacology*
  • Solid-Phase Synthesis Techniques
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Oligopeptides
  • lysyl-lysyl-leucyl-phenylalanyl-lysyl-lysyl-isoleucyl-leucyl-lysyl-tyrosyl-leucinamide